Viridian Therapeutics, Inc.\DE (VRDN) Enterprise Value (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Enterprise Value of -$762.2 million for Q1 2026, down 19.72% year-over-year from -$949.4 million in Q1 2025, and up 12.86% quarter-over-quarter from -$874.7 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Enterprise Value (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Enterprise Value history runs 14 years deep, the most recent figure standing at -$762.2 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 19.72% year-over-year to -$762.2 million; the TTM figure through Mar 2026 stood at -$762.2 million (down 19.72% YoY), while the FY2025 annual figure was -$874.7 million, down 21.89% from the prior year.
- Enterprise Value for Q1 2026 stood at -$762.2 million, up from -$874.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$161.2 million in Q2 2022, with the low at -$874.7 million in Q4 2025.
- The 5-year median for Enterprise Value is -$490.9 million (2025), against an average of -$510.2 million.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value tumbled 140.65% in 2024, then jumped 34.83% in 2025.
- Viridian Therapeutics, Inc.\DE's Enterprise Value stood at -$424.6 million in 2022, then declined by 12.44% to -$477.4 million in 2023, then sank by 50.32% to -$717.6 million in 2024, then slipped by 21.89% to -$874.7 million in 2025, then increased by 12.86% to -$762.2 million in 2026.
- Business Quant data shows VRDN's Enterprise Value at -$762.2 million in Q1 2026, -$874.7 million in Q4 2025, and -$490.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -981.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -981.53 Mn |
| Mar 31, 2026 | -762.18 Mn |
| Dec 31, 2025 | -874.65 Mn |
| Sep 30, 2025 | -490.90 Mn |
| Jun 30, 2025 | -563.36 Mn |
| Mar 31, 2025 | -636.63 Mn |
| Dec 31, 2024 | -717.58 Mn |
| Sep 30, 2024 | -753.24 Mn |
| Jun 30, 2024 | -571.37 Mn |
| Mar 31, 2024 | -613.19 Mn |
| Dec 31, 2023 | -477.37 Mn |
| Sep 30, 2023 | -313.01 Mn |
| Jun 30, 2023 | -334.29 Mn |
| Mar 31, 2023 | -373.86 Mn |
| Dec 31, 2022 | -424.55 Mn |
| Sep 30, 2022 | -431.32 Mn |
| Jun 30, 2022 | -161.21 Mn |
| Mar 31, 2022 | -175.43 Mn |
| Dec 31, 2021 | -196.97 Mn |
| Sep 30, 2021 | -213.81 Mn |